KMT2A and leukemia: However, another study using BET inhibitors to target leukemias induced by an MLL-AF9 fusion protein found that resistance emerges due to increased expression of Wnt/beta-catenin, presenting possible limitations regarding the use of BET inhibitors to treat MLL-associated leukemias [204].